Cargando…

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis

BACKGROUND: Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis. To date, little is known about this progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schimmelpennink, M. C., Meek, D. B., Vorselaars, A. D. M., Langezaal, L. C. M., van Moorsel, C. H. M., van der Vis, J. J., Veltkamp, M., Grutters, J. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233403/ https://www.ncbi.nlm.nih.gov/pubmed/35752806 http://dx.doi.org/10.1186/s12931-022-02094-7

Ejemplares similares

Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype
por: Beijer, Els, et al.
Publicado: (2021)

Quantification of pulmonary disease activity in sarcoidosis measured with (18)F-FDG PET/CT: SUVmax versus total lung glycolysis
por: Schimmelpennink, Milou C., et al.
Publicado: (2019)

ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis Patients
por: Karakaya, Bekir, et al.
Publicado: (2022)

Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension
por: Groen, Karlijn, et al.
Publicado: (2022)

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
por: Vorselaars, Adriane D. M., et al.
Publicado: (2013)

Simultaneous Assessment of mTORC1, JAK/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis
por: Kraaijvanger, Raisa, et al.
Publicado: (2023)

Home monitoring for patients with ILD and the COVID-19 pandemic
por: Nakshbandi, G, et al.
Publicado: (2020)

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis
por: Platenburg, Mark G. J. P., et al.
Publicado: (2023)

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study
por: Kahlmann, Vivienne, et al.
Publicado: (2020)

Moving from PF-ILD to PPF
por: Bhattacharyya, Parthasarathi
Publicado: (2023)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Genetic disorders of the surfactant system: focus on adult disease
por: van Moorsel, Coline H.M., et al.
Publicado: (2021)

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
por: Hoffman, Thijs W., et al.
Publicado: (2023)

Optimizing Screening for Early Disease Detection in Familial Pulmonary Fibrosis (FLORIS): A Prospective Cohort Study Design
por: Maus, Martijn T. K., et al.
Publicado: (2023)

TINF2 Gene Mutation in a Patient with Pulmonary Fibrosis
por: Hoffman, T. W., et al.
Publicado: (2016)

Pulmonary hypertension complicating pulmonary sarcoidosis
por: Huitema, M. P., et al.
Publicado: (2016)

Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects
por: Kraaijvanger, Raisa, et al.
Publicado: (2020)

Genetic Variant Overlap Analysis Identifies Established and Putative Genes Involved in Pulmonary Fibrosis
por: Groen, Karlijn, et al.
Publicado: (2023)

Sarcoidosis in a patient clinically diagnosed with silicosis; is silica associated sarcoidosis a new phenotype?
por: Beijer, Els, et al.
Publicado: (2019)

Latent tuberculosis infection associates with cardiac involvement in patients with sarcoidosis
por: Beijer, Els, et al.
Publicado: (2020)

Detection of Cutibacterium acnes in granulomas of patients with either hypersensitivity pneumonitis or vasculitis reveals that its presence is not unique for sarcoidosis
por: Beijer, Els, et al.
Publicado: (2021)

Establishing a Diagnosis of Pulmonary Sarcoidosis
por: Grutters, Jan C.
Publicado: (2023)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases
por: Enomoto, Noriyuki, et al.
Publicado: (2022)

The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review
por: Vis, Roeland, et al.
Publicado: (2020)

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
por: Moll, Sofia A., et al.
Publicado: (2020)

The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis
por: van Batenburg, Aernoud A., et al.
Publicado: (2021)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis
por: van Batenburg, Aernoud A., et al.
Publicado: (2020)

Thermal threshold testing: call for a balance between the number of measurements and abnormalities in the diagnosis of sarcoidosis-associated small fiber neuropathy
por: Raasing, Lisette R.M., et al.
Publicado: (2023)

Phenotypic Characterization of Human Intermediate Monocytes
por: Hijdra, Daniëlle, et al.
Publicado: (2013)

Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases
por: Moll, Sofia A., et al.
Publicado: (2022)

Outcomes in pulmonary sarcoidosis: results of a newly implemented prednisone protocol
por: Kampstra, Nynke A, et al.
Publicado: (2023)

Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients
por: Beijer, E., et al.
Publicado: (2020)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs
por: van Moorsel, Coline H. M., et al.
Publicado: (2015)

The usefulness of repeated CMR and FDG PET/CT in the diagnosis of patients with initial possible cardiac sarcoidosis
por: Mathijssen, H., et al.
Publicado: (2021)

Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis
por: Raasing, Lisette RM, et al.
Publicado: (2022)

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes
por: Kampstra, Nynke A., et al.
Publicado: (2019)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t87c6oh92l0td0m1tdavv8mv8n